Sterling Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Sterling Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-50,090	Closed	-$6.56M	–	947
2019 Q2	$6.56M	Buy	+50,090	New	+$6.46M	0.06%	223
2018 Q4	–	Sell	-32,797	Closed	-$4.56M	–	954
2018 Q3	$4.56M	Buy	32,797 +6,933	+27%	+$870K	0.04%	253
2018 Q2	$3.21M	Buy	25,864 +2,982	+13%	+$349K	0.03%	303
2018 Q1	$2.55M	Buy	22,882 +10,009	+78%	+$1.2M	0.02%	353
2017 Q4	$1.54M	Buy	12,873 +10,697	+492%	+$1.3M	0.01%	473
2017 Q3	$306K	Buy	+2,176	New	+$296K	﹤0.01%	826
2017 Q1	–	Sell	-1,992	Closed	-$244K	–	1026
2016 Q4	$244K	Buy	+1,992	New	+$244K	﹤0.01%	880
2016 Q2	–	Sell	-1,880	Closed	-$261K	–	1016
2016 Q1	$261K	Buy	+1,880	New	+$276K	﹤0.01%	836
2015 Q1	–	Sell	-6,146	Closed	-$1.14M	–	981
2014 Q4	$1.14M	Sell	6,146 -10,541	-63%	-$1.95M	0.01%	625
2014 Q3	$2.77M	Sell	16,687 -5,291	-24%	-$869K	0.03%	277
2014 Q2	$3.43M	Sell	21,978 -7,070	-24%	-$1.12M	0.03%	216
2014 Q1	$4.42M	Sell	29,048 -3,952	-12%	-$628K	0.04%	185
2013 Q4	$4.38M	Buy	+33,000	New	+$3.96M	0.04%	178

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sterling Capital Management's ALXN Position: Q3 2019 in Review

Sterling Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 50,090 shares — an estimated $6.56M sold.

Sterling Capital Management first reported a position in ALXN in Q4 2013 and held it in 13 quarters. The position peaked at $6.56M in Q2 2019. 648 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

Sterling Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Sterling Capital Management sold 50,090 Alexion Pharmaceuticals shares in Q3 2019, an estimated $6.56M.
Sterling Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 13 quarters.
Sterling Capital Management's Alexion Pharmaceuticals position peaked at $6.56M in Q2 2019.
648 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Sterling Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.